US Market Insights

Week One - July 26-30

US Market Outlook 2021: CDMO dealmaking in a pandemic and beyond

LIVE SESSION: July 26, 2 pm EST

Amidst a global pandemic, CDMOs were active in making acquisitions and investments. Our expert panelists discuss those deals, the challenges closing them and reflect on their relation to some of the broader themes and future trends for the US Pharmaceutical market.

Panel Discussion with GBR and contributors to the 2021 US Biopharmaceuticals Report:

Jason Spizer, Journalist, Global Business Reports
James Gale, Managing Director, Signet Healthcare Partners
Ramesh Subramanian, Chief Commercial Officer, Aragen
Robert Bloder, Chief Business Officer, Ascendia Pharmaceuticals INC.

Attendees will receive an interactive download of the 2021 US Biopharmaceuticals Report by GBR

COVID-19, the Future of Healthcare and Pandemics

On-Demand from July 27

Dr Scott Gottlieb, Physician & former FDA Commissioner

In this up to the moment session on the evolving state of healthcare, Dr. Scott Gottlieb will share the lessons learned from the COVID-19 Pandemic. Why events transpired, patterns that were deducted and how individuals, businesses and governments can be prepared to circumvent potential healthcare-related pitfalls in the future will be discussed. Attendees will take away knowledge that will advise business operations and decision making.

Week One - July 26-30

How will the New Administration Impact the US Pharma Market?

On-Demand from July 29

In January 2021, the U.S. Department of Health and Human Services and the Food and Drug Administration started operating under the new Biden Administration.

As always, Pharma played an integral part of the 2020 campaign, this session will deep-dive into the changes we can expect for the US market.

Discussion points:

Pricing and reimbursement strategies
What will the impact be on patients and payers?
The realities of reshoring manufacturing, can we expect to see reduced reliance on the East for essential medicines?
The R&D and innovation landscape

Speaker: Nielsen Hobbs Executive Editor, The Pink Sheet, Informa

This session was originally broadcast as part of CPhI Discover

M&A Climate & Current Market Dynamics

On-Demand from July 28

With over $1 trillion in M&A deals in the previous eight years, this trend in activity shows no signs of slowing with private equity firms capitalizing on the highly fragmented CDMO space. This webinar will address the benefits of private equity ownership, in triggering new growth, enabling greater strategic focus, increasing prioritization on M&A and better utilization of internal funds for organic growth initiatives.

Speakers:

Wayne P. Weiner, Pharmatech Solutions
David H. Windley, Jefferies
Rohan Saikia, Great Point Partners
Ilan Avni, Wavelength Pharmaceuticals

Discussion points:

Update on current M&A landscape
How to optimally position a company for first-time external investment
Life under PE: strategic support to the company’s management team,
The investor view: financing organic growth

Week One - July 26-30

How to Define Your Own Approach to Sustainability.

On-Demand from July 30

Pharmaceutical companies can not fulfil their core mission to improve public health without concurrently addressing our existential environmental risks and social inequities.

The most successful sustainability programs involve collaborations across all parts of the organization – e.g., research, engineering, manufacturing, procurement, human resources, corporate affairs, legal, finance.

This session will define your approach to sustainability from two perspectives: your organization’s and your personal contributions to advance the effort.

Speaker:

Tom Polton, Principal, NV Sustainability LCC